Avian (CCX) Cell Banks

About NUVONIS

Nuvonis operates as a specialized service and product provider in the biopharmaceutical manufacturing space, focusing on critical raw materials for viral vaccine and vector production. Its core assets are fully characterized, GMP-compliant Master and Working Cell Banks derived from a novel continuous quail cell line (CCX) and Vero cells, which aim to replace traditional substrates like chicken embryos. By offering these 'off-the-shelf' cell banks and associated process development expertise, Nuvonis positions itself as an enabler for biotech and pharma companies seeking to de-risk and accelerate their vaccine development programs. The company appears to be a private, likely pre-revenue or early-revenue entity serving a B2B clientele.

Therapeutic Areas

Other Vaccine/Vector Production Enabler Drugs